The FDA Peptides Hearing: What Happens July 23-24 and Why It Matters

Broadcast of the Pharmacy Compounding Advisory Committee Meeting Live Video

• July 23, 2026 | Watch
• July 24, 2026 | Watch

If you follow the landscape of peptide therapy, you have likely heard that a major regulatory event is approaching. Questions like “are peptides legal in 2026?” and “will BPC-157 be legal to compound?” have dominated wellness discussions in recent months. On July 23 and 24, 2026, the Food and Drug Administration (FDA) convenes its Pharmacy Compounding Advisory Committee (PCAC) for a highly anticipated two-day FDA peptides hearing^.1 This article breaks down the facts in plain language.

Key Takeaways

• The FDA’s advisory committee will evaluate whether seven specific peptides should be eligible for pharmacy compounding.
• The seven peptides are BPC-157, KPV, TB-500, MOTS-c, Emideltide (DSIP), Epitalon, and Semax. None is currently eligible for compounding.
• The committee’s vote is a recommendation to the FDA, not a final ruling, but it strongly influences the future regulatory pathway.
• The meeting is open to the public via live webcast.
• The FDA is accepting public comments on docket FDA-2025-N-6895 until July 22, 2026.

The regulatory process can be confusing, and there’s a lot of misinformation circulating about what this FDA peptide hearing is, what it can decide, and what it means for the future of peptide compounding. 

The agenda focuses on seven specific peptides that the FDA moved to Category 2 in 2023 (prohibiting compounding pharmacies from preparing them). Recently the seven compounds were removed from that category to undergo this formal peptide reclassification review.²

What Is the FDA Peptides Hearing?

The PCAC is an independent panel of experts that provides advice to the FDA on scientific, clinical, and medical issues related to compounded medications.¹

Under Section 503A of the Federal Food, Drug, and Cosmetic Act, for a licensed pharmacy to legally compound a medication from a bulk drug substance, that substance must meet certain criteria. If it does not have a USP monograph or is not a component of an FDA-approved drug, it must be placed on the FDA’s official 503A Bulks List.¹ This classification allows licensed pharmacies to use these substances when compounding medications for specific patients.

The PCAC is the body that reviews nominated substances and recommends whether they should be added to that list.

What the Hearing Will Do?

During the two-day meeting, the committee will review the clinical and safety evidence for each nominated peptide, hear presentations from the nominators, receive public comments from patients, clinicians, and industry professionals, and vote on a recommendation for each substance.¹

What the Hearing Will Not Do?

The PCAC does not make final laws. A committee vote is an advisory recommendation to the FDA, not a final rule. While the FDA generally follows the committee’s advice, the agency must still go through a formal rulemaking process before any substance is officially added to or excluded from the 503A Bulks List.¹

Who’s on the New FDA Peptide Advisory Committee?

The composition of the PCAC has shifted significantly for this hearing. Previous versions of the committee were primarily composed of academic researchers and scientists from institutions such as Duke University, Harvard, and Johns Hopkins. Those earlier panels reviewed peptide nominations multiple times and consistently voted against inclusion, citing insufficient human clinical evidence and unresolved safety questions.³

In April and May 2026, the FDA appointed eight new members to the committee. The restructured panel now includes 12 voting members, the majority of whom are wellness-focused physicians, compounding pharmacists, and practitioners with direct clinical experience prescribing or producing peptides. The chairperson position is currently vacant.⁴

The table below compares the general composition of the previous and current panels.

It is worth noting that FDA career scientists have independently published briefing documents for this hearing that recommend against easing restrictions on several of the peptides under review, citing insufficient evidence of effectiveness and unresolved safety questions.⁵ The committee’s vote will reflect the judgment of the new panel members, but the FDA is not required to follow their recommendation.

All advisory committee members are required to undergo a standard government ethics review before appointment. Financial disclosures are publicly available on the FDA’s advisory committee roster page.⁴

Which Peptides Are Being Evaluated for Compounding Eligibility?

The FDA has published briefing documents for the seven peptides that will be evaluated. The agency uses a four-part balancing test to evaluate substances: physical and chemical characterization, historical use in compounding, evidence of effectiveness, and safety.²

Here is a breakdown of the seven peptides on the agenda, what they are, and the therapeutic areas the FDA will evaluate.

BPC-157

When asking “is BPC-157 legal?”, the answer depends on the outcome of this hearing and subsequent rulemaking. Currently, BPC-157 is a 15-amino-acid synthetic peptide that comes from a protein found in human gastric juice. The FDA is evaluating BPC-157 specifically for ulcerative colitis. In experimental models, BPC-157 has been associated with enhanced angiogenesis (the formation of new blood vessels) and tissue repair.⁶ A 2026 FDA review noted that while animal data exists, human clinical trials using the proposed compounding routes are currently lacking.²

KPV

KPV is a naturally occurring tripeptide (lysine-proline-valine) derived from alpha-melanocyte-stimulating hormone. The FDA is evaluating KPV for wound healing and inflammatory conditions. Research suggests KPV works through melanocortin receptors to modulate inflammatory responses. KPV has been studied in cellular models for its potential anti-inflammatory effects, though the FDA noted an absence of human clinical trials.^2,7

TB-500

TB-500 is a synthetic fragment of thymosin beta-4, a naturally occurring protein involved in cell migration. The FDA is evaluating TB-500 for wound healing. The parent compound (thymosin beta-4) has been shown to accelerate wound healing in animal models.⁸ The FDA briefing document raised questions about whether the intact TB-500 peptide or its breakdown metabolites are responsible for the observed activity.²

MOTS-c

MOTS-c is a 16-amino-acid mitochondrial-derived peptide. The FDA is evaluating MOTS-c for obesity and osteoporosis. In animal models, MOTS-c was associated with improvements in metabolic homeostasis and insulin sensitivity.⁹ The FDA noted that human clinical evidence for these uses is currently absent.²

Emideltide (DSIP)

Emideltide, also known as Delta Sleep-Inducing Peptide (DSIP), is a neuropeptide first isolated in 1977. The FDA is evaluating emideltide for opioid withdrawal, chronic insomnia, and narcolepsy. DSIP has been studied for its potential to promote slow-wave (delta) sleep. While emideltide has a longer history of human study than some other peptides on this list, the FDA review characterized the existing trials as small and yielding inconsistent results.^2,10

Epitalon

Epitalon is a synthetic tetrapeptide studied for its effects on the pineal gland. The FDA is evaluating epitalon for insomnia. Nonclinical data indicates that epitalon may activate telomerase and lengthen telomeres in cellular models. The FDA noted that the long-term implications of telomerase activation require further characterization.²

Semax

Semax is a synthetic heptapeptide analog of ACTH with nootropic properties. The FDA is evaluating semax for cerebral ischemia, migraine, and trigeminal neuralgia. In animal models, semax has been associated with increased levels of Brain-Derived Neurotrophic Factor (BDNF).¹¹ The FDA review highlighted a need for more robust, controlled human trials for the evaluated conditions.²

How Can I Watch the FDA Peptides Hearing Live?

The PCAC process is open to the public. The meeting is at the FDA White Oak Campus in Silver Spring, Maryland, but it will also be broadcast live online via free webcast. YouTube Broadcast of the Pharmacy Compounding Advisory Committee (PCAC) Meeting Live Video

July 24, 2026 | Watch

July 23, 2026 | Watch

For those who want to read the FDA’s briefing documents, submit public comments, or find answers to commonly asked questions about the meeting, the FDA’s official advisory committee page is available here: FDA PCAC Meeting Page (July 23-24, 2026) The public comment period is open through July 22.

What Happens After the FDA Peptides Hearing?

The PCAC hearing is a big step in determining whether these seven peptides will become eligible for pharmacy compounding. If the committee recommends these peptides for the 503A Bulks List and the FDA agrees, it opens the door for licensed compounding pharmacies to legally prepare them under a physician’s prescription. If the panel recommends against inclusion, these peptides could remain ineligible for legal compounding. While the committee’s vote will not instantly change the legal status of these substances, it will provide a clear indication of how the FDA views the safety and efficacy data for these peptides.

The core question isn’t whether people will use these peptides — they already are. The question is whether they’ll get them from a licensed pharmacist or from an unregulated grey-market source online.

The best course of action is to stay informed, rely on regulatory updates from PeptideMatch, and always discuss your wellness goals with a licensed healthcare provider who understands the current compounding landscape.

Scientific References

1. Food and Drug Administration. July 23-24, 2026: Meeting of the Pharmacy Compounding Advisory Committee. Advisory Committee Calendar. 2026.
2. Food and Drug Administration. Pharmacy Compounding Advisory Committee Meeting Briefing Documents. 2026.
3. Chang CH, Tsai WC, Lin MS, Hsu YH, Pang JH. Pentadecapeptide BPC 157 enhances the growth hormone receptor expression in tendon fibroblasts. Molecules. 2014;19(11):19066-19077.
4. Xiao B, Xu Z, Viennois E, et al. Orally targeted delivery of tripeptide KPV via hyaluronic acid-functionalized nanoparticles efficiently alleviates ulcerative colitis. Molecular Therapy. 2017;25(7):1628-1640.
5. Malinda KM, Sidhu GS, Mani H, et al. Thymosin beta4 accelerates wound healing. Journal of Investigative Dermatology. 1999;113(3):364-368.
6. Lee C, Zeng J, Drew BG, et al. The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance. Cell Metabolism. 2015;21(3):443-454.
7. Kovalzon VM, Strekalova TV. Delta sleep-inducing peptide (DSIP): a still unresolved riddle. Journal of Neurochemistry. 2006;97(2):303-309.
8. Dergunova LV, Filippenkov IB, Limborska SA, Bhatt P. Neuroprotective peptides and new strategies for ischemic stroke drug discovery. Genes. 2023;14(5):953.
9. Perrone M. FDA panel on peptides will include experts who promote the unproven chemicals favored by RFK Jr. Associated Press. June 29, 2026.
10. Food and Drug Administration. Pharmacy Compounding Advisory Committee Roster. Updated June 29, 2026.
11. FDA scientists warn against expanded peptide access as Kennedy reshapes advisory panel. HealthDay News/Neurology Advisor. July 8, 2026.

Legal & Medical Disclaimer

The information provided on this page by PeptideMatch.io is intended solely for educational and informational purposes. It does not constitute, and should not be interpreted as, professional medical advice, diagnosis, or treatment. Always consult a licensed physician or qualified healthcare provider before beginning any peptide therapy or making changes to an existing treatment plan. PeptideMatch.io does not prescribe, dispense, or endorse any specific therapeutic protocol. Individual results may vary, and no outcomes are guaranteed.

©2026 PeptideMatch.io. All Rights Reserved. This educational content is the exclusive intellectual property of PeptideMatch.io. Reproduction, distribution, republication, or transmission of this material, in whole or in part, in any form or by any means, is strictly prohibited without the prior written consent of PeptideMatch.io. For licensing or reprint inquiries, please contact content@peptidematch.io.